The Associated Press - Business News on MSN16d
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...
Merck’s soft guidance overshadows quarterly beat to send stock down 6%
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...
Daily1d
Merck Welireg receives European Commission nod for two indications
Rahway: Merck, known as MSD outside of the United States and Canada, has received conditional approval from the European ...
Seeking Alpha6d
MRK Merck & Co., Inc.
and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck: Q4 Earnings Snapshot
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...
Yahoo Finance23d
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
RAHWAY, N.J., January 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly ...
Wall Street Journal16d
Merck Earnings Rise; 2025 Outlook Hits Shares
Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, though the drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares. The ...
Merck sales forecast underwhelms as it pauses some shipments to China
Shares of Merck slid on Tuesday in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling ...